brusatol has been researched along with Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinghorn, AD; Ren, Y | 1 |
| He, T; Li, Z; Mi, L; Su, A; Wu, W; Xing, Z; Zhang, Y; Zhou, F | 1 |
| Kang, JS; Keum, YS; Nam, LB; Yoo, OK | 1 |
| Guo, R; Ren, F; Tian, Z; Yang, Y | 1 |
2 review(s) available for brusatol and Neoplasms
| Article | Year |
|---|---|
Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica.
Topics: Antineoplastic Agents; Brucea javanica; Humans; Neoplasms; Quassins; Seeds | 2023 |
Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.
Topics: Animals; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; NF-E2-Related Factor 2; Quassins; Tretinoin | 2020 |
2 other study(ies) available for brusatol and Neoplasms
| Article | Year |
|---|---|
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Diterpenes; Humans; Neoplasms; Sesquiterpenes; Structure-Activity Relationship; Triterpenes | 2020 |
Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways.
Topics: Animals; Antineoplastic Agents, Immunological; Brucea; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasms; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-akt; Quassins; Transfection; Trastuzumab | 2020 |